WASHINGTON, April 6, 2026, 17:00 EDT
UnitedHealth Group shares climbed in after-hours trading Monday, following news that the U.S. locked in a 2.48% hike to 2027 Medicare Advantage payment rates—well above the almost unchanged rate floated back in January. The move also gave a lift to Humana and CVS stocks.
Timing could be key here. UnitedHealth’s first-quarter numbers land before the bell on April 21—a date investors have circled since January, after the company put out an alert that 2026 revenue would dip for the first time in decades. That warning, combined with the government’s initial rate proposal, has only heightened anxiety over a potential prolonged margin squeeze.
Medicare Advantage—private insurers running government-funded plans for seniors—remains a major profit engine in the industry. The CMS on Monday said the finalized 2027 rules will boost plan payments by over $13 billion, beating some analysts’ expectations ahead of the announcement.
“These updates keep coverage affordable and ensure patients get real value from their plans,” CMS Administrator Mehmet Oz said. The higher rate lands as a boost for UnitedHealth, which has its Optum health-services and pharmacy arms to offset pressure—unlike Humana, with less diversification. CVS, for its part, operates a wider set of businesses beyond Medicare Advantage. CMS
UnitedHealth plans to announce its first-quarter 2026 results on April 21, according to a March 17 statement. TipRanks analysts are looking for earnings per share of around $6.65, which would be an 8% drop from last year, with revenue estimates at about $109.58 billion. Following meetings with management, the company reiterated that it still anticipates roughly 65% of its 2026 earnings to come in during the first half.
Not everyone on Wall Street is ready to throw in the towel. Last week, Raymond James analyst John Ransom bumped UnitedHealth up to outperform, setting a $330 price target. He says there’s still space for the company to trim overhead and work margins back up after the recent selloff.
Stephen Hemsley, now back in charge as chief executive, wants to pitch 2026 as a reset, not a step back. “Momentum inside this organization is palpable,” he said in January. UnitedHealth’s outlook for 2026? Revenue topping $439 billion, with adjusted earnings per share above $17.75. Reuters
The rate boost leaves tougher issues unresolved. CMS is sticking with stricter risk-adjustment measures—the system that increases payments for plans covering sicker enrollees—and plans to drop diagnoses from chart reviews not linked to actual patient visits. Back in January, Morningstar’s Julie Utterback flagged that investors banking on a speedy rebound “may have to wait longer than hoped.” CMS
April 21 now stands out as the date to watch for UnitedHealth stock. Should medical costs show signs of retreat and the company sticks with its full-year outlook, Monday’s policy move could signal a more stable period ahead. But if costs fail to cooperate, the reimbursement bump may serve as little more than padding—a temporary fix. Humana and CVS will be eyeing the outcome too, both tracking how it plays out in their own Medicare lines.
